Pharmacology: Rifaximin is a non-aminoglycoside, semi-synthetic, antibacterial derived from Rifamycin. Rifaximin acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase resulting in inhibition of bacterial RNA synthesis.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education